References
- Beedham C. Molybdenum hydroxylases as drug-metabolizing enzymes. Drug Metabolism Reviews 1985; 16: 119–156
- Beedham C. Molybdenum hydroxylases: Biological distribution and substrate-inhibitor specificity. Progress in Medicinal Chemistry 1987; 24: 85–121
- Beedham C. The role of non-P450 enzymes in drug oxidation. Pharmacy World Science 1997; 19: 255–263
- Beedham C. Molybdenum hydroxylase. Enzyme systems that metabolise drug and other xenobiotics, C Ioannides. Wiley, London 2002; 147–187
- Beedham C, Al-Tayib Y, Smith JA. The role of guinea pig and rabbit hepatic aldehyde oxidase in the oxidative in vitro metabolism of cinchona alkaloids. Drug Metabolism and Disposition 1992; 20: 889–895
- Beedham C, Miceli JJ, Obach S. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. Journal of Clinical Psychopharmacology 2003; 23: 229–232
- Hill R, Nishino T. Xanthine oxidase and xanthine dehydrogenase. FASEB Journal 1995; 9: 995–1003
- Itoh K, Masubuchi A, Sasaki T, Adachi M, Watanabe N, Nagata K, Yamazoe Y, Hiratsuka M, Mizugaki M, Tanaka Y. Genetic polymorphism of aldehyde oxidase in Donryu rats. Drug Metabolism and Disposition 2007; 35: 734–739
- Itoh K, Yamamura M, Muramatsu S, Hoshino K, Masubuchi A, Sasaki T, Tanaka Y. Stereospecific oxidation of (S)-enantiomer of RS-8359, a selective and reversible MAO-A inhibitor, by aldehyde oxidase. Xenobiotica 2005; 35: 561–573
- Itoh K, Yamamura M, Takasaki W, Sasaki T, Masubuchi A, Tanaka Y. Species differences in enantioselective 2-oxidation of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase. Biopharmaceutics and Drug Disposition 2006; 27: 133–139
- Jordan CGM, Rashidi MR, Laljee H, Clarke SE, Brown JE, Beedham C. Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea pig, rabbit and man. Journal of Pharmacy and Pharmacology 1999; 51: 411–418
- Kitamura S, Nakatani K, Sugihara K, Ohta S. Strain differences of the ability to hydroxylate methotrexate in rats. Comparative Biochemistry and Physiology Part C 1999b; 122: 331–336
- Kitamura S, Sugihara K, Nakatani K, Ohta S, O’Hara T, Nimomiya S, Green CE, Tyson CA. Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. UBMB Life 1999a; 48: 607–611
- Kitamura S, Sugihara K, Ohta S. Drug-metabolizing ability of molybdenum hydroxylases. Drug Metabolism Pharmacokinetics 2006; 21: 83–98
- Kunieda T, Kobayashi E, Tachibana M, Ikadai H. A genetic linkage map of rat chromosome 9 with a new locus for variant activity of liver aldehyde oxidase. Experimental Animals 1999; 48: 43–45
- Miura H, Naoi M, Nakahara D, Ohta T, Nagatsu T. Changes in monoamine levels in mouse brain elicited by forced-swimming stress, and the protective effect of a new monoamine oxidase inhibitor, RS-8359. Journal of Neural Transmission 1993; 94: 175–187
- Plenker A, Puchler K, Volz HP. The effects of RS-8359 on cardiovascular function in healthy subjects and depressed patients. International Clinical Psychopharmacology 1997; 12: S25–S29
- Prakash C, Kamel A, Gummerus J, Wilner K. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metabolism and Disposition 1997; 25: 863–875
- Puchler K, Schaffler K, Plenker A. The comparative effects of single and multiple doses of RS-8359, moclobemide and placebo on psychomotor function in healthy subjects. International Clinical Psychopharmacology 1997; 12: S17–S23
- Rashidi MR, Smith JA, Clarke SE, Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit and rat liver. Drug Metabolism and Disposition 1997; 25: 805–813
- Sasaki T, Masubuchi A, Yamamura M, Watanabe N, Hiratsuka M, Mizugaki M, Itoh K, Tanaka Y. Rat strain differences in stereospecific 2-oxidation of RS-8359, a reversible and selective MAO-A inhibitor, by aldehyde oxidase. Biopharmaceutics and Drug Disposition 2006; 27: 247–255
- Sugihara K, Kitamura S, Tatsumi K. Strain differences of liver aldehyde oxidase activity in rat. Biochemistry and Molecular Biology International 1995; 41: 1153–1160
- Takasaki W, Yamamura M, Nozaki A, Nitanai T, Sasahara K, Itoh K, Tanaka Y. Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug metabolizing enzymes. Chirality 2005; 17: 135–141
- Yokoyama T, Karube T, Iwata N. Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in vitro and in vivo in mouse brain. Journal of Pharmacy and Pharmacology 1989; 41: 32–36